A randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy

Lawrence B. Cohen, Edward Cattau, Allen Goetsch, Atul Shah, John R. Weber, Douglas Rex, Jacqueline M. Kline

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Goals: This double-blind, multicenter study evaluated the safety and efficacy of intravenous fospropofol (6.5mg/kg vs. 2mg/kg) for moderate sedation in patients undergoing colonoscopy. Methods: In all, 314 patients 18 years (American Society of Anesthesiologists PS1 to PS3) were randomized to receive fospropofol 2mg/kg, fospropofol 6.5-mg/kg, or midazolam 0.02mg/kg, after pretreatment with intravenous fentanyl 50mcg. Supplemental doses of study medication were permitted to achieve a Modified Observer's Assessment of Alertness/Sedation scale score ≤4 and to enable the investigator to begin a procedure. The study end points included sedation success, recovery, memory retention, physician satisfaction, and safety. Results: Sedation success was higher in the fospropofol 6.5mg/kg versus 2mg/kg group (87% vs. 26%; P<0.001) and was 69% in the midazolam group. Patients in the 6.5-mg/kg group were significantly less likely to remember being awake during the procedure (51% vs. 100% in the 2-mg/kg group, P<0.001; 60% for the midazolam group). Patients in the fospropofol groups had similar memory retention (70% and 82% for the 6.5mg/kg and 2mg/kg groups, respectively) compared with 41% for the midazolam group. Mean physician satisfaction scores were higher in the fospropofol 6.5-mg/kg group (7.7) than the 2-mg/kg group (4.5), P<0.001. Most adverse events were mild to moderate in intensity; the most common treatment-related adverse events were paresthesias (68% vs. 60%) and pruritus (16% vs. 26%) in the fospropofol 6.5 and 2mg/kg groups, respectively. Conclusions: The fospropofol 6.5-mg/kg dosing regimen was well tolerated and effective for sedation during colonoscopy and was associated with higher rates of sedation success, memory retention, and physician satisfaction than the fospropofol 2-mg/kg dose.

Original languageEnglish
Pages (from-to)345-353
Number of pages9
JournalJournal of Clinical Gastroenterology
Volume44
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Colonoscopy
Midazolam
Physicians
Conscious Sedation
Safety
fospropofol
Paresthesia
Fentanyl
Pruritus
Double-Blind Method
Multicenter Studies
Research Personnel

Keywords

  • Colonoscopy
  • Fospropofol disodium
  • Moderate sedation
  • Randomized clinical trial

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy. / Cohen, Lawrence B.; Cattau, Edward; Goetsch, Allen; Shah, Atul; Weber, John R.; Rex, Douglas; Kline, Jacqueline M.

In: Journal of Clinical Gastroenterology, Vol. 44, No. 5, 05.2010, p. 345-353.

Research output: Contribution to journalArticle

Cohen, Lawrence B. ; Cattau, Edward ; Goetsch, Allen ; Shah, Atul ; Weber, John R. ; Rex, Douglas ; Kline, Jacqueline M. / A randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy. In: Journal of Clinical Gastroenterology. 2010 ; Vol. 44, No. 5. pp. 345-353.
@article{e7c26d48a87d4dd49923138d3ea25dd6,
title = "A randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy",
abstract = "Goals: This double-blind, multicenter study evaluated the safety and efficacy of intravenous fospropofol (6.5mg/kg vs. 2mg/kg) for moderate sedation in patients undergoing colonoscopy. Methods: In all, 314 patients 18 years (American Society of Anesthesiologists PS1 to PS3) were randomized to receive fospropofol 2mg/kg, fospropofol 6.5-mg/kg, or midazolam 0.02mg/kg, after pretreatment with intravenous fentanyl 50mcg. Supplemental doses of study medication were permitted to achieve a Modified Observer's Assessment of Alertness/Sedation scale score ≤4 and to enable the investigator to begin a procedure. The study end points included sedation success, recovery, memory retention, physician satisfaction, and safety. Results: Sedation success was higher in the fospropofol 6.5mg/kg versus 2mg/kg group (87{\%} vs. 26{\%}; P<0.001) and was 69{\%} in the midazolam group. Patients in the 6.5-mg/kg group were significantly less likely to remember being awake during the procedure (51{\%} vs. 100{\%} in the 2-mg/kg group, P<0.001; 60{\%} for the midazolam group). Patients in the fospropofol groups had similar memory retention (70{\%} and 82{\%} for the 6.5mg/kg and 2mg/kg groups, respectively) compared with 41{\%} for the midazolam group. Mean physician satisfaction scores were higher in the fospropofol 6.5-mg/kg group (7.7) than the 2-mg/kg group (4.5), P<0.001. Most adverse events were mild to moderate in intensity; the most common treatment-related adverse events were paresthesias (68{\%} vs. 60{\%}) and pruritus (16{\%} vs. 26{\%}) in the fospropofol 6.5 and 2mg/kg groups, respectively. Conclusions: The fospropofol 6.5-mg/kg dosing regimen was well tolerated and effective for sedation during colonoscopy and was associated with higher rates of sedation success, memory retention, and physician satisfaction than the fospropofol 2-mg/kg dose.",
keywords = "Colonoscopy, Fospropofol disodium, Moderate sedation, Randomized clinical trial",
author = "Cohen, {Lawrence B.} and Edward Cattau and Allen Goetsch and Atul Shah and Weber, {John R.} and Douglas Rex and Kline, {Jacqueline M.}",
year = "2010",
month = "5",
doi = "10.1097/MCG.0b013e3181c2987e",
language = "English",
volume = "44",
pages = "345--353",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A randomized, double-blind, phase 3 study of fospropofol disodium for sedation during colonoscopy

AU - Cohen, Lawrence B.

AU - Cattau, Edward

AU - Goetsch, Allen

AU - Shah, Atul

AU - Weber, John R.

AU - Rex, Douglas

AU - Kline, Jacqueline M.

PY - 2010/5

Y1 - 2010/5

N2 - Goals: This double-blind, multicenter study evaluated the safety and efficacy of intravenous fospropofol (6.5mg/kg vs. 2mg/kg) for moderate sedation in patients undergoing colonoscopy. Methods: In all, 314 patients 18 years (American Society of Anesthesiologists PS1 to PS3) were randomized to receive fospropofol 2mg/kg, fospropofol 6.5-mg/kg, or midazolam 0.02mg/kg, after pretreatment with intravenous fentanyl 50mcg. Supplemental doses of study medication were permitted to achieve a Modified Observer's Assessment of Alertness/Sedation scale score ≤4 and to enable the investigator to begin a procedure. The study end points included sedation success, recovery, memory retention, physician satisfaction, and safety. Results: Sedation success was higher in the fospropofol 6.5mg/kg versus 2mg/kg group (87% vs. 26%; P<0.001) and was 69% in the midazolam group. Patients in the 6.5-mg/kg group were significantly less likely to remember being awake during the procedure (51% vs. 100% in the 2-mg/kg group, P<0.001; 60% for the midazolam group). Patients in the fospropofol groups had similar memory retention (70% and 82% for the 6.5mg/kg and 2mg/kg groups, respectively) compared with 41% for the midazolam group. Mean physician satisfaction scores were higher in the fospropofol 6.5-mg/kg group (7.7) than the 2-mg/kg group (4.5), P<0.001. Most adverse events were mild to moderate in intensity; the most common treatment-related adverse events were paresthesias (68% vs. 60%) and pruritus (16% vs. 26%) in the fospropofol 6.5 and 2mg/kg groups, respectively. Conclusions: The fospropofol 6.5-mg/kg dosing regimen was well tolerated and effective for sedation during colonoscopy and was associated with higher rates of sedation success, memory retention, and physician satisfaction than the fospropofol 2-mg/kg dose.

AB - Goals: This double-blind, multicenter study evaluated the safety and efficacy of intravenous fospropofol (6.5mg/kg vs. 2mg/kg) for moderate sedation in patients undergoing colonoscopy. Methods: In all, 314 patients 18 years (American Society of Anesthesiologists PS1 to PS3) were randomized to receive fospropofol 2mg/kg, fospropofol 6.5-mg/kg, or midazolam 0.02mg/kg, after pretreatment with intravenous fentanyl 50mcg. Supplemental doses of study medication were permitted to achieve a Modified Observer's Assessment of Alertness/Sedation scale score ≤4 and to enable the investigator to begin a procedure. The study end points included sedation success, recovery, memory retention, physician satisfaction, and safety. Results: Sedation success was higher in the fospropofol 6.5mg/kg versus 2mg/kg group (87% vs. 26%; P<0.001) and was 69% in the midazolam group. Patients in the 6.5-mg/kg group were significantly less likely to remember being awake during the procedure (51% vs. 100% in the 2-mg/kg group, P<0.001; 60% for the midazolam group). Patients in the fospropofol groups had similar memory retention (70% and 82% for the 6.5mg/kg and 2mg/kg groups, respectively) compared with 41% for the midazolam group. Mean physician satisfaction scores were higher in the fospropofol 6.5-mg/kg group (7.7) than the 2-mg/kg group (4.5), P<0.001. Most adverse events were mild to moderate in intensity; the most common treatment-related adverse events were paresthesias (68% vs. 60%) and pruritus (16% vs. 26%) in the fospropofol 6.5 and 2mg/kg groups, respectively. Conclusions: The fospropofol 6.5-mg/kg dosing regimen was well tolerated and effective for sedation during colonoscopy and was associated with higher rates of sedation success, memory retention, and physician satisfaction than the fospropofol 2-mg/kg dose.

KW - Colonoscopy

KW - Fospropofol disodium

KW - Moderate sedation

KW - Randomized clinical trial

UR - http://www.scopus.com/inward/record.url?scp=77951714320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951714320&partnerID=8YFLogxK

U2 - 10.1097/MCG.0b013e3181c2987e

DO - 10.1097/MCG.0b013e3181c2987e

M3 - Article

VL - 44

SP - 345

EP - 353

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 5

ER -